Jean De Vry

Summary

Affiliation: Bayer AG
Country: Germany

Publications

  1. ncbi request reprint Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat
    Jean De Vry
    CNS Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany
    Eur J Pharmacol 505:127-33. 2004
  2. ncbi request reprint Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism
    J De Vry
    CNS Research, Bayer AG, Wuppertal, Germany
    Eur Neuropsychopharmacol 9:461-8. 1999
  3. ncbi request reprint Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A
    Jean De Vry
    CNS Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany
    Eur J Pharmacol 483:55-63. 2004
  4. ncbi request reprint Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine
    J De Vry
    CNS Research, Bayer Health Care, Aprather Weg 18a, 42096 Wuppertal, Germany
    Behav Pharmacol 14:229-35. 2003
  5. ncbi request reprint Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist
    Jean De Vry
    CNS Research, Bayer Health Care, Aprather Weg 18a, D 42096 Wuppertal, Germany
    Eur J Pharmacol 457:147-52. 2002
  6. ncbi request reprint Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action
    J De Vry
    CNS Research, Bayer AG, Aprather Weg 18, D 42096, Wuppertal, Germany
    Neurosci Biobehav Rev 24:341-53. 2000
  7. doi request reprint Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist
    Frank G Boess
    Pharma Research CNS, Bayer HealthCare AG, 42096, Wuppertal, Germany
    Psychopharmacology (Berl) 227:1-17. 2013
  8. ncbi request reprint BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury
    Frank Mauler
    Bayer HealthCare PH R EU CNS, Aprather Weg 18a, D 42096 Wuppertal, Germany
    CNS Drug Rev 9:343-58. 2003
  9. ncbi request reprint Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties
    Frank Mauler
    CNS Research, Bayer AG, Business Group Pharma, Aprather Weg 18a, 42096 Wuppertal, Germany
    J Pharmacol Exp Ther 302:359-68. 2002
  10. ncbi request reprint Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat
    Rudy Schreiber
    CNS Research, Bayer AG, Wuppertal, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 26:441-9. 2002

Collaborators

Detail Information

Publications19

  1. ncbi request reprint Discriminative stimulus effects of the structurally novel cannabinoid CB1/CB2 receptor partial agonist BAY 59-3074 in the rat
    Jean De Vry
    CNS Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany
    Eur J Pharmacol 505:127-33. 2004
    ..It is concluded that the discriminative stimulus effects of BAY 59-3074 are specifically mediated by cannabinoid CB1 receptor activation...
  2. ncbi request reprint Comparison of hypericum extracts with imipramine and fluoxetine in animal models of depression and alcoholism
    J De Vry
    CNS Research, Bayer AG, Wuppertal, Germany
    Eur Neuropsychopharmacol 9:461-8. 1999
    ..The present study suggests that hypericum extracts have antidepressant-like properties which resemble those of clinically established antidepressants, and that Remotiv may be an interesting adjunct for the treatment of alcoholism...
  3. ncbi request reprint Behavioral mechanisms underlying inhibition of food-maintained responding by the cannabinoid receptor antagonist/inverse agonist SR141716A
    Jean De Vry
    CNS Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany
    Eur J Pharmacol 483:55-63. 2004
    ..45 mg/kg). Although the data support the suggestion that the anorectic effect of SR141716A results from an attenuating effect on the rewarding effect of food, the contribution of drug-induced aversion/malaise cannot be excluded...
  4. ncbi request reprint Role of the NMDA receptor NR2B subunit in the discriminative stimulus effects of ketamine
    J De Vry
    CNS Research, Bayer Health Care, Aprather Weg 18a, 42096 Wuppertal, Germany
    Behav Pharmacol 14:229-35. 2003
    ..These findings suggest that the NR2B subunit is involved in the discriminative stimulus effects of noncompetitive NMDA antagonists, and that selective NR2B antagonists may also induce psychotomimetic side-effects...
  5. ncbi request reprint Discriminative stimulus effects of BAY 38-7271, a novel cannabinoid receptor agonist
    Jean De Vry
    CNS Research, Bayer Health Care, Aprather Weg 18a, D 42096 Wuppertal, Germany
    Eur J Pharmacol 457:147-52. 2002
    ..28 mg/kg] and (-)-Delta(9)-tetrahydrocannabinol (0.34 mg/kg). The present study confirms that BAY 38-7271 is a highly potent cannabinoid CB(1) receptor agonist in vivo...
  6. ncbi request reprint Effects of selected serotonin 5-HT(1) and 5-HT(2) receptor agonists on feeding behavior: possible mechanisms of action
    J De Vry
    CNS Research, Bayer AG, Aprather Weg 18, D 42096, Wuppertal, Germany
    Neurosci Biobehav Rev 24:341-53. 2000
    ....
  7. doi request reprint Pharmacological and behavioral profile of N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141), a novel α7 nicotinic acetylcholine receptor agonist/serotonin 5-HT3 receptor antagonist
    Frank G Boess
    Pharma Research CNS, Bayer HealthCare AG, 42096, Wuppertal, Germany
    Psychopharmacology (Berl) 227:1-17. 2013
    ..This study describes the in vitro pharmacology of the novel α7 nAChR agonist/serotonin 5-HT3 receptor (5-HT3R) antagonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-6-chinolincarboxamide (EVP-5141) and its behavioral effects...
  8. ncbi request reprint BAY 38-7271: a novel highly selective and highly potent cannabinoid receptor agonist for the treatment of traumatic brain injury
    Frank Mauler
    Bayer HealthCare PH R EU CNS, Aprather Weg 18a, D 42096 Wuppertal, Germany
    CNS Drug Rev 9:343-58. 2003
    ....
  9. ncbi request reprint Characterization of the diarylether sulfonylester (-)-(R)-3-(2-hydroxymethylindanyl-4-oxy)phenyl-4,4,4-trifluoro-1-sulfonate (BAY 38-7271) as a potent cannabinoid receptor agonist with neuroprotective properties
    Frank Mauler
    CNS Research, Bayer AG, Business Group Pharma, Aprather Weg 18a, 42096 Wuppertal, Germany
    J Pharmacol Exp Ther 302:359-68. 2002
    ..It is concluded that the CB1/CB2 receptor agonist BAY 38-7271 shows pronounced neuroprotective properties that do not result from drug-induced hypothermia and that occur in a dose range devoid of typical cannabinoid-like side effects...
  10. ncbi request reprint Role of 5-hT2C receptors in the hypophagic effect of m-CPP, ORG 37684 and CP-94,253 in the rat
    Rudy Schreiber
    CNS Research, Bayer AG, Wuppertal, Germany
    Prog Neuropsychopharmacol Biol Psychiatry 26:441-9. 2002
    ..The results further indicate that simultaneous activation of 5-HT2C and 5-HT1B receptors underlies the higher potency of m-CPP in reducing food intake, as compared with other, more selective, compounds...
  11. ncbi request reprint Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice
    Rudy Schreiber
    CNS Research, Bayer AG, Aprather Weg 18a, 42096 Wuppertal, Germany
    Psychopharmacology (Berl) 159:248-57. 2002
    ..This variability may be due to differences in the tested dose range, selectivity of the test compound, species and strain, and suggests that nAChR subtypes are differentially involved in the control of auditory gating...
  12. ncbi request reprint 3-[2-cyano-3-(trifluoromethyl)phenoxy]phenyl-4,4,4-trifluoro-1-butanesulfonate (BAY 59-3074): a novel cannabinoid Cb1/Cb2 receptor partial agonist with antihyperalgesic and antiallodynic effects
    Jean De Vry
    Central Nervous System Research, Bayer HealthCare, Wuppertal, Germany
    J Pharmacol Exp Ther 310:620-32. 2004
    ..No withdrawal symptoms were seen after abrupt withdrawal following 14 daily applications of 1 to 10 mg/kg p.o. It is concluded that BAY 59-3074 may offer a valuable therapeutic approach to treat diverse chronic pain conditions...
  13. ncbi request reprint Pharmacological characterization of the chronic constriction injury model of neuropathic pain
    Jean De Vry
    CNS Research, Bayer HealthCare, Aprather Weg 18a, 42096 Wuppertal, Germany
    Eur J Pharmacol 491:137-48. 2004
    ....
  14. ncbi request reprint Pharmacological sensitivity and gene expression analysis of the tibial nerve injury model of neuropathic pain
    Heiko A Hofmann
    CNS Research, Bayer Health Care, Aprather Weg 18a, D 42096, Wuppertal, Germany
    Eur J Pharmacol 470:17-25. 2003
    ....
  15. ncbi request reprint The novel alpha7 nicotinic acetylcholine receptor agonist N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-7-[2-(methoxy)phenyl]-1-benzofuran-2-carboxamide improves working and recognition memory in rodents
    Frank G Boess
    Pharma Research CNS, Medicinal Chemistry, Bayer HealthCare AG, Wuppertal, Germany
    J Pharmacol Exp Ther 321:716-25. 2007
    ..Our results support the hypothesis that alpha7 nAChR agonists may provide a novel therapeutic strategy for the treatment of cognitive deficits with low abuse potential...
  16. ncbi request reprint The serotonin/noradrenaline reuptake inhibitor venlafaxine attenuates acquisition, but not maintenance, of intravenous self-administration of heroin in rats
    Zofia Magalas
    Department of Pharmacology, Preclinical Research and Development, Grunenthal GmbH, 52099 Aachen, Germany
    Eur J Pharmacol 528:103-9. 2005
    ..Thus, daily treatment with an antidepressant attenuates the acquisition of heroin self-administration in a behaviourally specific manner, while having only marginal effects on maintenance of heroin self-administration...
  17. ncbi request reprint (-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Aachen, Germany
    J Pharmacol Exp Ther 323:265-76. 2007
    ..It is suggested that the broad analgesic profile of tapentadol and its relative resistance to tolerance development may be due to a dual mode of action consisting of both MOR activation and NE reuptake inhibition...
  18. ncbi request reprint Effect of 2-methyl-6-(phenylethynyl) pyridine on intravenous self-administration of ketamine and heroin in the rat
    Elizabeth L van der Kam
    Grunenthal GmbH, Preclinical Research and Development, Department of Pharmacology, Aachen, Germany
    Behav Pharmacol 18:717-24. 2007
    ..It is suggested that the differential effect of MPEP on IVSA of ketamine and heroin is related to the particular class of the self-administered drug or its relative reinforcing efficacy...
  19. ncbi request reprint Effects of venlafaxine and desipramine on heroin-induced conditioned place preference in the rat
    Thomas M Tzschentke
    Department of Pharmacology, Grunenthal GmbH, Germany
    Addict Biol 11:64-71. 2006
    ..Alternatively, the modulation of acquisition of heroin IVSA in the previous study may be related to mechanisms that cannot be modelled with the CPP paradigm...